ClinicalTrials.gg
CompletedNCT00901264MiCKUpdated Nov 14, 2012

Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients

An observational study in Cancer, sponsored by Pierian Biosciences. Completed at 11 sites in 2 countries. Per ClinicalTrials.gov, last updated 2012-11-14.

Sponsored by Pierian Biosciences · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
300
Sex
All
01

Study summary

The purpose of this study is to correlate the results of the MICK assay with short- and long-term results of treatments in cancer patients and evaluate the role of the MiCK assay in guiding chemotherapy of cancer patients.

Read the detailed description

Identification of those patients with cancer who will or will not respond to a specific chemotherapy is important for making decisions regarding chemotherapy regimens as well as alternative management approaches. A laboratory test that could help to determine the sensitivity of an individual patient's tumor cells to specific chemotherapeutic agents would be valuable in choosing the optimal chemotherapy regimen for that patient with an expectation of increasing the response rate to the therapy. Several types of in vitro assays that measure tumor cell survival following exposure to cytotoxic agents have been evaluated for their ability to predict chemotherapy outcomes. As a group, these assays are referred to as drug resistance assays. In a resistance assay, the surviving tumor cells can be detected directly by their exclusion or metabolism of specific dyes. Alternatively, since some of tumor cells are proliferating, their survival can be detected by measurement of DNA synthesis by radiolabeled precursor incorporation or demonstration of clonogenic potential by growth into colonies in semi-solid culture medium. In several clinical studies, these assays were useful in detecting drug resistance and in predicting a poor prognosis for cancer patients. However, these resistance assays cannot detect sensitivity of an individual patient's tumor cells to a specific drug. Therefore, new methods determining drug-sensitivity of the tumor cells of an individual patient and, thus, capable of both predicting a positive treatment outcome and guiding chemotherapy, would be of significant value.

Recently, an automated microculture kinetic (MiCK) assay for measuring drug induced apoptosis in tumor cells has been developed1-4. Apoptosis is a distinct mode of cell death which occurs under physiological conditions and yet can be induced in malignant cells by chemical and physical factors including antitumor drugs5-7. During the last decade, it has been recognized that chemotherapeutic agents exert their antitumor activity by triggering apoptosis in susceptible tumor cells8-17. This implies that the MiCK assay for apoptosis provides a mechanism-based approach to studying effects of cytotoxic agents on tumor cells. Unlike "resistance" assays that measure a fraction of cells surviving drug exposure, the MiCK assay measures a fraction of tumor cells killed by a chemotherapeutic agent via mechanism of apoptosis. Therefore the MiCK assay determines drug sensitivity, rather than resistance. Recently the MiCK assay has been shown to predict complete remission rate and survival in acute myeloid leukemia patients better than clinical criteria did18-20. In a limited study, the MiCK assay has been used to direct chemotherapy of the leukemia patients 21.

The MiCK assay has also been used to study drug-induced apoptosis in solid tumors, including neuroblastoma and colon adenocarcinoma cell lines22-23. More recent data accumulated by DiaTech has demonstrated that the MiCK assay can detect drug induced apoptosis in primary cultures of tumor cells isolated from patients with ovarian carcinoma, gastric carcinoma, metastatic breast cancer and high grade soft tissue sarcoma. The purpose of this study is to correlate the results of the MICK assay with short- and long-term results of treatments in cancer patients and evaluate the role of the MiCK assay in guiding chemotherapy of cancer patients.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • Chemosensitivity, chemotherapy, all cancers, personalized chemotherapy, personalized cancer treatment
  • Cancer Patients for whom chemotherapy is planned.
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 300 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Pierian Biosciences is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cancer Patients for whom chemotherapy is planned.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 3.1.1 Patients with pathological diagnoses of cancer or leukemia
  • 3.1.2 Patients must have tumor which is accessible for and agree to undergo tumor biopsy, or drainage of malignant effusion, and the specimen must be submitted for MiCK assay.
  • 3.1.3 Patients for whom chemotherapy is planned.

Exclusion criteria

Exclusion Criteria:

  • 3.2.1 Patients with symptomatic/uncontrolled parenchymal brain or meningeal and tumors not accessible for .
  • 3.2.2 Patients who are pregnant. Pregnancy. During the course of the study, all patients of should be instructed to contact the treating physician if they suspect they might have conceived a child; for females, a missing or late menstrual period should be reported to the treating physician. If pregnancy is confirmed by a pregnancy test, the patient must not receive chemotherapy in this study and must not be enrolled into the study or, if already enrolled, must be withdrawn from the study. If a male patient is suspected of having fathered a child while on the study, the pregnant female partner must be notified and counseled regarding the risk to the fetus. Pregnancy during the course of this study will be reported to the Principal Investigator as a serious adverse event. Women of child bearing potential are defined to include any female who has experienced menarche and has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not (defined as amenorrhea for more than 12 consecutive months); these includes also females using oral, implanted, or injectable hormones, mechanical devices, or barrier methods to prevent pregnancy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
300 participants (actual)

Groups and cohorts

  • 1

    Patients with pathological diagnoses of cancer or leukemia

  • 2

    3.1.3 Patients for whom chemotherapy is planned.

06

What researchers measure

Primary outcomes

  1. To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients, with emphasis on patients failing primary treatment, patients with unknown primary tumors, and patients with tumors difficult to treat such as carcinoma of lung.

    Time frame: one year

Secondary outcomes

  1. Correlate the MiCK assay results with objective response rates, symptom response rates, time to progression and survival of cancer patients treated with chemotherapy.

    Time frame: one year

07

Study locations

11 sites
  • Wilshire Oncology Medical Group, Inc
    La Verne, California 91750, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • DiaTech Oncology
    Brentwood, Tennessee 37027, United States
  • Cumberland Medical Center
    Crossville, Tennessee 38555, United States
  • Middle Tennessee Medical Center
    Murfreesboro, Tennessee 37219, United States
  • Baptist Hospital
    Nashville, Tennessee 37203, United States
  • Nashville Oncology Associates
    Nashville, Tennessee 37203, United States
  • St. Thomas Research Institute, LLC
    Nashville, Tennessee 37203, United States
  • Tennessee Breast Specialists
    Nashville, Tennessee 37203, United States
  • Tennessee Toracic Surgical Specialists
    Nashville, Tennessee 37205, United States
  • DiaTech Oncology
    Montreal, Quebec H2X 3P9, Canada
08

References and documents

Publications

  • Bosserman L, Rogers K, Willis C, Davidson D, Whitworth P, Karimi M, Upadhyaya G, Rutledge J, Hallquist A, Perree M, Presant CA. Application of a drug-induced apoptosis assay to identify treatment strategies in recurrent or metastatic breast cancer. PLoS One. 2015 May 29;10(5):e0122609. doi: 10.1371/journal.pone.0122609. eCollection 2015. PubMed 26024531 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2009
First posted
May 13, 2009
Start
Dec 2008
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Nov 14, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00901264
Lead sponsor
Pierian Biosciences
Responsible party
Sponsor
First posted
May 13, 2009
Start date
Dec 2008
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Nov 14, 2012

Study contacts

Cary Presant, MD
study director · Pierian Biosciences
Dirk Davidson, MD
principal investigator · Cumberland Medical Center
Karl Rogers, MD
principal investigator · Nashville Oncology Associates
Swapnil P. Rajurkar, MD
principal investigator · Wilshire Oncology Medical Group, Inc.
Laura Lawson, MD
principal investigator · Tennessee Breast Specialists
L. James Wudel Jr., MD
principal investigator · Tennessee Thoracic Surgical Specialists
Raymond F Bluth, MD
principal investigator · Baptist Hospital Nashville
Peter F Jelsma, MD
principal investigator · St. Thomas Research Institute, LLC
Richard D Michaelson, MD
principal investigator · Middle Tennessee Medical Center
Jorge E Marcet, MD
principal investigator · Tampa Gerneral Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion